Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 35.03B | 33.07B | 42.87B | 34.34B | 51.08B | 30.09B |
Gross Profit | 24.73B | 21.55B | 31.25B | 25.46B | 40.62B | 22.27B |
EBITDA | 2.56B | -2.88B | 10.53B | 6.97B | 21.88B | 10.18B |
Net Income | -228.00M | -4.76B | 5.51B | 3.77B | 14.51B | 6.89B |
Balance Sheet | ||||||
Total Assets | 105.52B | 104.86B | 102.23B | 94.94B | 97.13B | 73.78B |
Cash, Cash Equivalents and Short-Term Investments | 15.51B | 13.20B | 18.76B | 13.28B | 30.98B | 26.26B |
Total Debt | 32.39B | 38.10B | 23.30B | 22.80B | 18.10B | 18.10B |
Total Liabilities | 52.55B | 57.42B | 45.75B | 42.52B | 46.05B | 35.23B |
Stockholders Equity | 52.58B | 47.04B | 56.18B | 52.16B | 50.88B | 38.38B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -15.37B | 7.22B | -14.06B | -2.04B | 2.81B |
Operating Cash Flow | 0.00 | -5.49B | 9.31B | -5.50B | 9.29B | 10.34B |
Investing Cash Flow | 0.00 | -9.87B | -2.69B | -15.00B | -3.25B | -3.29B |
Financing Cash Flow | 0.00 | 9.74B | -2.03B | 1.95B | -2.18B | 8.30B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | ¥65.25B | 13.63 | 2.03% | 2.06% | -32.48% | ||
71 Outperform | ¥78.43B | 9.42 | 0.67% | 8.83% | 70.61% | ||
67 Neutral | €98.72B | 18.09 | 4.35% | 2.76% | 5.31% | 90.37% | |
64 Neutral | ¥90.87B | 67.37 | 2.35% | 0.80% | 5.94% | -45.43% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
48 Neutral | $79.27B | ― | -3.36% | ― | 87.83% | 75.84% | |
45 Neutral | ¥63.86B | ― | 3.77% | -22.86% | -188.19% |
JCR Pharmaceuticals Co., Ltd. announced a plan to dispose of 111,000 shares of its treasury stock as part of a restricted stock compensation plan aimed at incentivizing its directors and employees. This initiative is designed to align the interests of the company’s leadership with those of its shareholders, promoting sustained corporate value enhancement and ensuring continued commitment from key personnel.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
JCR Pharmaceuticals Co., Ltd. has announced its relationship with MEDIPAL HOLDINGS CORPORATION, which is its largest shareholder with a 23.86% voting rights ownership. The companies have a business alliance to enhance corporate value and growth, leveraging MEDIPAL’s distribution strengths and JCR’s pharmaceutical R&D capabilities. Recent agreements between the two include exclusive negotiation rights for the global commercialization of JCR’s new drug candidates targeting ultra-rare lysosomal storage diseases, and licensing agreements for treatments like JR-471 and JR-446. These collaborations are expected to bolster JCR’s industry positioning and operational capabilities.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen590.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
JCR Pharmaceuticals Co., Ltd. has announced a recognition of gain on deferred income taxes for the fiscal year ended March 31, 2025, resulting in a corporate tax adjustment profit of 1,771 million yen. This adjustment reflects the company’s performance trends and careful review of deferred tax assets’ recoverability, impacting the consolidated financial results positively and demonstrating JCR’s strategic financial management.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
JCR Pharmaceuticals has announced a leadership transition effective April 1, 2026, marking a generational shift as the company celebrates its 50th anniversary. Toru Ashida will become Chairman and Hiroyuki Sonoda will assume the role of President, while current Chairman, President, and CEO Shin Ashida will transition to Founder and Director. This change aims to strengthen the management structure and enhance long-term corporate value.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
JCR Pharmaceuticals reported a significant decline in its financial performance for the fiscal year ending March 31, 2025, with net sales dropping by 22.9% and a net loss of 4,759 million yen. The company is undergoing changes, including the exclusion of Mycenax Biotech Inc. from its subsidiaries and adjustments in accounting policies, as it aims to improve its financial standing and operational efficiency in the coming fiscal year.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
JCR Pharmaceuticals Co., Ltd. announced the distribution of retained earnings as dividends, with a term-end dividend of 10.00 yen per share for the fiscal year ending March 31, 2025, matching the previous year’s dividend. This decision aligns with JCR’s policy of consistent profit distribution while maintaining reserves for new drug development and financial stability.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen700.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
JCR Pharmaceuticals Co., Ltd. announced the nomination of new candidates for its Audit & Supervisory Board, with appointments to be confirmed at the upcoming Ordinary General Meeting of Shareholders. This change reflects a strategic move to refresh its governance structure, potentially impacting its operational oversight and stakeholder confidence.